Search Result
Results for "
lipoproteins
" in MedChemExpress (MCE) Product Catalog:
8
Biochemical Assay Reagents
8
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-113288
-
|
|
Others
|
Metabolic Disease
|
|
Campestanol is a phytosterol that can be found in plant food. Campestanol lowers serum cholesterol and low-density lipoprotein. Campestanol can be used for the research of metabolic disorders .
|
-
-
- HY-117549
-
|
NO-1886
|
Others
|
Cardiovascular Disease
|
|
Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL)-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects .
|
-
-
- HY-116977
-
|
|
Others
|
Metabolic Disease
|
|
Binifibrate is an active compound and has a beneficial effect on lipoprotein metabolism. Binifibrate can be used for the research of hyperlipidemia .
|
-
-
- HY-115914
-
|
|
Others
|
Others
|
|
Lipid-lowering agent-1 is a potent lipid-lowering agent. Lipid-lowering agent-1 has significant pharmacological effects on the inhibition of low-density lipoprotein cholesterol (LDLC) and promotion of high-density lipoprotein cholesterol (HDLC) production. Lipid-lowering agent-1 shows potent hypolipidemic effect in high-fat diet rats .
|
-
-
- HY-147279
-
|
|
LDLR
|
Others
|
|
Milpocitide is a low-density lipoprotein receptor (human LDL receptor, LDLR), (293-333)-peptide fragment (EGF-like domain 1) .
|
-
-
- HY-158424
-
|
|
Others
|
Cardiovascular Disease
|
|
LSN3353871 is a potent inhibitor of lipoprotein(a) (Lp(a)) that can binds to Kringle IV (KIV) 8, KIV7–8 and KIV5–8, with Kd of 756 nM, 605 nM and 423 nM, respectively. LSN3353871 disrupts the formation of Lp(a) with the IC50 of 1.69 µM. LSN3353871 has oral bioactivity .
|
-
-
- HY-123039
-
|
|
CETP
|
Metabolic Disease
|
|
CP-532623 is a CETP inhibitor and elevates high-density lipoprotein cholesterolion. CP-532623 is a close structural analogue of Torcetrapib. CP-532623 has highly lipophilic properties .
|
-
-
- HY-142669
-
|
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
|
Lp-PLA2-IN-4 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-4 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 38) .
|
-
-
- HY-142670
-
|
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
|
Lp-PLA2-IN-5 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-5 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 32) .
|
-
-
- HY-142779
-
|
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
|
Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-11 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2014114249A1, compound E145) .
|
-
-
- HY-142778
-
|
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
|
Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-10 has the potential for the research of neurodegenerative-related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis (extracted from patent WO2022001881A1, compound 4) .
|
-
-
- HY-109523
-
|
|
HMG-CoA Reductase (HMGCR)
Ferroptosis
|
Cardiovascular Disease
Cancer
|
|
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
|
-
-
- HY-145001
-
|
|
Others
|
Metabolic Disease
|
|
20-HC-Me-Pyrrolidine is a potent Aster protein inhibitor with IC50s of 0.11 μM, 0.06 μM, and 0.71 μM for Aster-A, Aster-B, and Aster-C, respectively. 20-HC-Me-Pyrrolidine blocks the ability of Asters to bind and transfer cholesterol. 20-HC-Me-Pyrrolidine also inhibits the movement of low-density lipoprotein (LDL) cholesterol to the endoplasmic reticulum (ER) .
|
-
-
- HY-129458
-
|
|
HMG-CoA Reductase (HMGCR)
Ferroptosis
|
Cardiovascular Disease
Cancer
|
|
Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
|
-
-
- HY-153451
-
|
|
PCSK9
|
Metabolic Disease
|
|
PCSK9-IN-15 (compound 5) is a potent inhibitor of proprotein convertase subtilisin/kexin 9 (PCSK9, KD <200 nM). PCSK9 is involved in cholesterol metabolism and regulates levels of low-density lipoprotein cholesterol (LDL-C) in the blood. PCSK9- in -15 can be used to study cholesterol-lowering and dyslipidemia .
|
-
-
- HY-109523S
-
|
|
Ferroptosis
HMG-CoA Reductase (HMGCR)
Isotope-Labeled Compounds
|
Cardiovascular Disease
Cancer
|
|
Cerivastatin-d3 sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
|
-
-
- HY-116767
-
BLT-1
3 Publications Verification
Block lipid transport-1
|
HCV
|
Metabolic Disease
Inflammation/Immunology
|
|
BLT-1, a thiosemicarbazone copper chelator, is a selective scavenger receptor B, type 1 (SR-BI) inhibitor. BLT-1 inhibits the transfer of lipids between high-density lipoproteins (HDL) and cells mediated by SR-BI. BLT-1 is a potent HCV entry inhibitor .
|
-
-
- HY-P2752
-
|
LPL
|
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
|
Lipoprotein lipase, Pseudomonas sp (LPL) is a multifunctional enzyme from adipose tissue, heart and skeletal muscle, islets and macrophages. Lipoprotein lipase promotes normal lipoprotein metabolism, delivery and utilization of tissue-specific substrates. Lipoprotein lipase catalyzes the rate-limiting step of lipids in blood circulation .
|
-
-
- HY-NP013
-
|
Mouse ox-LDL
|
LDLR
|
Cardiovascular Disease
|
|
Oxidized low density lipoprotein (mouse) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration .
|
-
-
- HY-17504B
-
|
ZD 4522 Sodium; X-Plended Sodium; Crestor Sodium
|
HMG-CoA Reductase (HMGCR)
Potassium Channel
Autophagy
Bacterial
|
Cardiovascular Disease
Metabolic Disease
|
|
Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
|
-
-
- HY-NP135
-
|
Human ox-LDL
|
NO Synthase
NOD-like Receptor (NLR)
|
Metabolic Disease
Inflammation/Immunology
|
|
Oxidized low density lipoprotein (Human) (Human ox-LDL) is involved in atherogenesis. Oxidized low density lipoprotein (Human) induces endothelial dysfunction via cytoplasmic adapter protein TRAF3IP2. Oxidized low density lipoprotein (Human) can stimulate the activation of endothelial cells and the production of adhesion molecules, and inhibits eNOS activity and NO production. Oxidized low density lipoprotein (Human) can activate NLRP3 inflammasome in macrophages .
|
-
-
- HY-17504BS2
-
|
ZD 4522-13C,d3 sodium; X-Plended-13C,d3 sodium; Crestor-13C,d3 sodium
|
Autophagy
Bacterial
HMG-CoA Reductase (HMGCR)
Potassium Channel
Isotope-Labeled Compounds
|
Cardiovascular Disease
Metabolic Disease
|
|
Rosuvastatin- 13C,d3 sodium is 13C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
|
-
-
- HY-17504
-
|
Rosuvastatin hemicalcium; ZD 4522 Calcium
|
HMG-CoA Reductase (HMGCR)
Autophagy
Potassium Channel
Bacterial
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
|
-
-
- HY-106278A
-
|
|
PPAR
|
Metabolic Disease
|
|
GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 significantly increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol, and significantly reduced triglycerides. The maximum increases in HDL cholesterol for GW 590735 were 37%, 53% and 84%, respectively, compared with bezafibrate, torcetrapib and GW 590735 .
|
-
-
- HY-153492A
-
-
-
- HY-17504A
-
|
ZD 4522
|
HMG-CoA Reductase (HMGCR)
Autophagy
Potassium Channel
Bacterial
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
|
-
-
- HY-148626
-
|
|
PCSK9
|
Metabolic Disease
|
|
CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .
|
-
-
- HY-N13235
-
|
|
Others
|
Cardiovascular Disease
|
|
Garlic Extract is a garlic extract, and its components include: Allicin. Garlic Extract is beneficial to cardiovascular disease and has the potential to reduce the risk of cardiovascular disease. Garlic Extract can effectively reduce total cholesterol, low-density lipoprotein levels and improve high-density lipoprotein levels. .
|
-
-
- HY-157536
-
|
|
Bacterial
|
Infection
|
|
SMT-738 is a small-molecule inhibitor of bacterial lipoprotein transport targeting Enterobacteriaceae .
|
-
-
- HY-P99793
-
|
MLDL1278A
|
LDLR
|
Inflammation/Immunology
|
|
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .
|
-
-
- HY-132303
-
|
|
CETP
|
Cardiovascular Disease
Metabolic Disease
|
|
MK-8262 is an orally active and potent cholesteryl ester transfer protein (CETP) inhibitor with an IC50 of 53 nM and a log D of 5.3. MK-8262, a bistrifluoromethyl analogue, has the potential for coronary heart disease (CHD) correlated high-density lipoprotein (HDL) and low-density lipoprotein (LDL) research .
|
-
-
- HY-109567
-
|
PD-72953
|
Others
|
Metabolic Disease
Inflammation/Immunology
|
|
Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .
|
-
-
- HY-120651
-
|
|
LDLR
|
Metabolic Disease
|
|
LDL-IN-2 (compound 3) is an antioxidant against copper mediated low-density lipoproteins (LDL) oxidation .
|
-
-
- HY-N8353
-
|
|
Others
|
Metabolic Disease
|
|
Stachybotramide is a natural fungal metabolite with the property of modulating the activity of cholesteryl ester transfer protein (CETP). Stachybotramide stimulates the transfer of cholesteryl esters (CE) from high-density lipoprotein (HDL) to very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), increasing the transfer efficiency by 1.3- to 1.5-fold. Stachybotramide slightly reduced the transfer of cholesteryl esters from LDL and VLDL to HDL at 0.5 mM. The effect of Stachybotramide on the transfer of triglycerides (TG) from HDL was not significant. By these results, Stachybotramide was shown to preferentially stimulate the CETP-mediated transfer of cholesteryl esters from HDL to VLDL and LDL .
|
-
-
- HY-109567A
-
|
PD-72953 calcium
|
Others
|
Metabolic Disease
Inflammation/Immunology
|
|
Gemcabene calcium (PD-72953 calcium), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .
|
-
-
- HY-D0083
-
|
DiIC18(3)
|
Fluorescent Dye
|
Others
|
|
DiI is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .
|
-
-
- HY-D0969
-
|
DiOC18(3); 3,3'-Dioctadecyloxacarbocyanine perchlorate
|
Fluorescent Dye
|
Others
|
|
DiO is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .
|
-
-
- HY-D1028
-
|
|
Fluorescent Dye
|
Others
|
|
DiD is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .
|
-
-
- HY-D1048
-
|
Cy7 DiC18
|
Fluorescent Dye
|
Cancer
|
|
DiR is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .
|
-
-
- HY-46749
-
|
LY3473329 tetrahydrochloride
|
Others
|
Cardiovascular Disease
|
|
Muvalaplin tetrahydrochloride (LY3473329) is an orally active reagent of lipoprotein (a) (Lp (a)). At present, research on Muvalaplin tetrahydrochloride oral reagent is ongoing .
|
-
-
- HY-N0483
-
|
Phillygenol; Epipinoresinol methyl ether; (+)-Phillygenin
|
Reactive Oxygen Species
|
Others
|
|
Phillygenin (Phillygenol) is an active ingredient from Forsythia with many medicinal properties, such as antioxidant, reducing blood lipid, inhibition of low density lipoprotein oxidation.
|
-
-
- HY-100901
-
|
|
Cytochrome P450
|
Metabolic Disease
|
|
CDD3505 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.
|
-
-
- HY-100902
-
|
|
Cytochrome P450
|
Metabolic Disease
|
|
CDD3506 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.
|
-
-
- HY-123260
-
|
|
LDLR
|
Cardiovascular Disease
|
|
S12340 is a a inhibitor of the oxidative modification of low-density lipoprotein and shows protective effect on cardiac cells exposed to oxidative stress .
|
-
-
- HY-14456A
-
|
|
Bacterial
|
Infection
|
|
MAC13243, an antibacterial agent, is an inhibitor of bacterial lipoprotein targeting chaperone, LolA. MAC13243 is an antibacterial agent with Gram-negative selectivity .
|
-
-
- HY-W041171
-
|
3-Chlorotyrosine
|
Endogenous Metabolite
|
Others
|
|
3-Chloro-L-tyrosine is a specific marker of myeloperoxidase-catalyzed oxidation, and is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima.
|
-
-
- HY-D0932
-
|
Solvent Red 24; C.I. 26105
|
Fluorescent Dye
|
Others
|
|
Sudan IV (Solvent Red 24) is a lysochrome (fat-soluble dye) diazo dye used for the staining of lipids, triglycerides and lipoproteins on frozen sections .
|
-
-
- HY-N2339
-
|
Cholesteryl docosanoate; Cholesterol behenate
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.
|
-
-
- HY-N5015
-
|
|
COX
|
Inflammation/Immunology
Cancer
|
|
Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.
|
-
-
- HY-D1076
-
|
|
Fluorescent Dye
|
Metabolic Disease
|
|
DiIC16(3) is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .
|
-
- HY-153497
-
|
IONIS ANGPT-L3Rx; ISIS 703802
|
ANGPTL
|
Metabolic Disease
|
|
Vupanorsen is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen lowers triglycerides and atherogenic lipoproteins.
|
-
- HY-153497A
-
|
IONIS ANGPT-L3Rx sodium; ISIS 703802 sodium
|
ANGPTL
|
Metabolic Disease
|
|
Vupanorsen (sodium) is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen (sodium) lowers triglycerides and atherogenic lipoproteins.
|
-
- HY-112540B
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Acetoacetic acid sodium is a metabolite of non-esterified fatty acids, involved in the development of human diabetes. Acetoacetic acid sodium induces oxidative stress to inhibit the assembly of very low density lipoprotein in bovine hepatocytes .
|
-
- HY-120984
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
AcylCoA:cholesterol acyltransferase (ACAT) is an intracellular cholesteryl ester synthase tied closely to the absorption of dietary cholesterol.1 Oleic acid-2,6-diisopropylanilide is an inhibitor of acylCoA:cholesterol acyltransferase with an IC50 of 7 nM.2 When co-administered to rabbits or rats fed a high fat, high cholesterol diet, oleic acid-2,6-diisopropylanilide decreased low density lipoproteins and elevated high density lipoprotein levels when administered at 0.05%.
|
-
- HY-161940
-
|
|
PCSK9
|
Cardiovascular Disease
|
|
PCSK9-IN-30 (Compound 3f) is a PCSK9 inhibitor. PCSK9-IN-30 interacts with a cryptic binding groove of PCSK9, inhibiting the binding of PCSK9 to the low-density lipoprotein receptor (LDLR) (IC50 = 537 nM), restoring the uptake of low-density lipoprotein (LDL) by liver cells, and ultimately reducing plasma cholesterol levels. PCSK9-IN-30 exhibits good bioavailability in mice and can be used for research in the field of cardiovascular diseases .
|
-
- HY-121776
-
|
|
Others
|
Cardiovascular Disease
|
|
Nicomol is an orally active hypolipidemic agent that can increase the high density lipoprotein cholesterol (HDL-C) level. Nicomol inhibits the rapid rise of plasma free fatty acids .
|
-
- HY-W020798
-
|
|
Fluorescent Dye
|
Others
|
|
1-Palmitoyl-2-[3-(diphenylhexatriene)propanoyl]-sn-phosphatidylcholine is a fluorescent probe with a polar phosphatidylethanolamine head group for the determination of surface lipid oxidation in lipoproteins and plasma .
|
-
![1-Palmitoyl-2-[3-(diphenylhexatriene)propanoyl]-sn-phosphatidylcholine](//file.medchemexpress.eu/product_pic/hy-w020798.gif)
- HY-153561A
-
|
|
Phospholipase
|
Neurological Disease
|
|
Lp-PLA2-IN-16 (example 1) is a lipoprotein-associated phospholipase A2 (Lp-PLA 2) inhibitor, which can be used in the research of Alzheimer's disease, etc .
|
-
- HY-153561
-
|
|
Phospholipase
|
Neurological Disease
|
|
Lp-PLA2-IN-15 (example 2) is a lipoprotein-associated phospholipase A2 (Lp-PLA 2) inhibitor, which can be used in the research of Alzheimer's disease, etc .
|
-
- HY-130576
-
|
|
Apoptosis
|
Cardiovascular Disease
|
|
POVPC is an oxidized phospholipid can be found in in oxidatively modified low density lipoprotein (oxLDL). POVPC inhibits VSMC growth in high serum condition. POVPC induces apoptosis in low serum condition .
|
-
- HY-W510159
-
|
|
PCSK9
|
Cardiovascular Disease
|
|
5-O-Methylembelin is a natural isocoumarin that inhibits PCSK9, inducible degrader of the low-density lipoprotein receptor (IDLR), and sterol regulatory element binding protein 2 (SREBP2) mRNA expression .
|
-
- HY-W134326
-
|
|
Biochemical Assay Reagents
|
Metabolic Disease
Cancer
|
|
Polydextrose has the effect of lowering cholesterol and plasma lipids, and can effectively reduce low-density lipoprotein cholesterol. Polydextrose significantly reduced plasma and liver cholesterol in gerbils fed with enlarged endogenous cholesterol reservoirs .
|
-
- HY-169114
-
|
|
5-HT Receptor
Phospholipase
|
Cardiovascular Disease
|
|
Goxalapladib is a 5-HT6 receptor modulator that blocks lipoprotein-associated phospholipase A2 (Lp-PLA2) activity. Goxalapladib is promising for research of atherosclerosis-associated cardiovascular diseases .
|
-
- HY-148758
-
|
|
PCSK9
|
Metabolic Disease
|
|
PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC50 of 537 nM .
|
-
- HY-W719862
-
|
|
Liposome
|
Others
|
|
16:0 PDP PE belongs to a class of head group modified functionalized lipids. 16:0 PDP PE has been used in preparation of rhodamine high-density lipoprotein nanoparticle (Rh-HDL NP) synthesis.
|
-
- HY-102004
-
|
SB 659032
|
Phospholipase
|
Neurological Disease
Inflammation/Immunology
|
|
Rilapladib (SB 659032) is a selective Lp-PLA2 (lipoprotein-associated phospholipase A2) inhibitor with an IC50 of 230 pM . Rilapladib (SB 659032) is also a PAFR (Platelet Activating Factor Receptor) antagonist .
|
-
- HY-133148
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
Lp-PLA2-IN-2 is a potent and selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 0f 120 nM for recombinant human Lp-PLA2 .
|
-
- HY-19757
-
-
- HY-133149
-
|
|
Phospholipase
|
Cardiovascular Disease
|
|
Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2) .
|
-
- HY-145653
-
-
- HY-139414
-
|
|
Interleukin Related
p38 MAPK
ERK
Apoptosis
|
Inflammation/Immunology
|
|
Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis .
|
-
- HY-D0932S
-
|
Solvent Red 24-d6; C.I. 26105-d6
|
Isotope-Labeled Compounds
|
Others
|
|
Sudan IV-d6 is the deuterium labeled Sudan IV(HY-D0932).Sudan IV is a lysochrome (fat-soluble dye) diazo dye used for the staining of lipids, triglycerides and lipoproteins on frozen paraffin sections .
|
-
- HY-N5015R
-
|
|
COX
|
Inflammation/Immunology
Cancer
|
|
Rosmanol (Standard) is the analytical standard of Rosmanol. This product is intended for research and analytical applications. Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.
|
-
- HY-D0932R
-
|
|
Fluorescent Dye
|
Others
|
|
Sudan IV (Standard) is the analytical standard of Sudan IV. This product is intended for research and analytical applications. Sudan IV (Solvent Red 24) is a lysochrome (fat-soluble dye) diazo dye used for the staining of lipids, triglycerides and lipoproteins on frozen sections .
|
-
- HY-124658
-
|
|
Bacterial
|
Infection
|
|
G0507, a pyrrolopyrimidinedione compound, is a potent LolCDE ABC Transporter inhibitor. G0507 is a inhibitor of Escherichia coli growth and induces the extracytoplasmic σE stress response. G0507 acts as a chemical probe to dissect lipoprotein trafficking in Gram-negative bacteria .
|
-
- HY-B1189S
-
|
Dicrotalic acid-d3; 3-Hydroxy-3-methylglutaric acid-d3
|
Autophagy
HMG-CoA Reductase (HMGCR)
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Meglutol-d3 is the deuterium labeled Meglutol[1]. Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.
|
-
- HY-126463
-
|
|
Bacterial
|
Infection
|
|
LolCDE-IN-4 (Compound 1) is exhibits antibacterial efficacy against gram negative bacteria Escherichia coli (MIC of 0.25-32 µg/ml) and Haemophilus influenzae, through inhibition LolCDE complex and disruption of lipoproteins release from the inner membrane .
|
-
- HY-P10389
-
|
|
Bacterial
|
Infection
|
|
Globomycin derivative G2A (Compound G2A) is an inhibitor for lipoprotein signal peptidase II (LspA), with an IC50 of 604 nM. Globomycin derivative G2A inhibits E. coli, P. aeruginosa and A. baumannii, with MIC ranging from 12.5 to 32 μg/mL .
|
-
- HY-12089
-
|
CP-529414
|
CETP
|
Endocrinology
|
|
Torcetrapib (CP-529414) is a selective, potent cholesteryl ester transfer protein (CETP) inhibitor. A typical inhibition curve for whole human plasma, having a CETP concentration of 37 nM .
|
-
- HY-101529
-
|
HOE-402(free base)
|
LDLR
|
Cardiovascular Disease
|
|
Imanixil (HOE-402 free base) is an inducer of the LDL receptor (LDLR). Imanixil (HOE-402 free base) is also a potent cholesterol-lowering compound, which inhibits very low density-lipoprotein (VLDL) production, and consequently attenuates atherosclerosis development .
|
-
- HY-123494
-
|
|
Others
|
Cardiovascular Disease
Neurological Disease
|
|
BRD0418 is a diversity-oriented synthesis (DOS) molecule that regulates the expression of tribbles pseudokinase 1. BRD0418 has the effect of causing hot lipoprotein metabolism from fat production to clearance. BRD0418 can be used in the study of coronary artery disease (CAD) .
|
-
- HY-113269
-
|
|
Others
|
Others
|
|
alpha-CEHC is a water-soluble metabolite of alpha-tocopherol (α-TOH) with potential antioxidant activity. alpha-CEHC slightly inhibits macrophage-induced low-density lipoprotein (LDL) oxidation, and its inhibitory potency is concentration-dependent .
|
-
- HY-N7072
-
|
|
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Grape seed extract is a natural product, with anti-inflammatory and anti-proliferative effects. Grape seed extract shows inhibitory activity on the fat-metabolizing enzymes pancreatic lipase and lipoprotein lipase. Grape seed extract induces apoptotic in human colorectal cancer cells .
|
-
- HY-W709553
-
|
Triglyceride
|
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Glyceryl Triformate (Triglyceride) is the major form of storage and transport of fatty acids within cells and in the plasma. Glyceryl Triformate forms lipoproteins with cholesterol ester, and participates in the blood circulation. Glyceryl Triformate can lead to hypertriglyceridemia (HTG), which increases the risk of atherosclerotic cardiovascular disease (ASCVD) and pancreatitis .
|
-
- HY-161942
-
|
|
PCSK9
|
Metabolic Disease
|
|
PCSK9-IN-31 (Compound WX002) is an orally active PCSK9 inhibitor. PCSK9-IN-31 can lower low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) in high cholesterol fed model rats .
|
-
- HY-128334
-
|
|
PCSK9
|
Metabolic Disease
|
|
PCSK9 modulator-2 (Compound 1) is a potent modulator of PCSK9 with an EC50 value of 202 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-2 has the potential for the research of hyperlipidemia .
|
-
- HY-16274
-
|
TAK-475
|
Others
|
Metabolic Disease
|
|
Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway . Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research .
|
-
- HY-N0120
-
|
(E/Z)-Piceid
|
Others
|
Inflammation/Immunology
|
|
(E/Z)-Polydatin ((E/Z)-Piceid) is a monocrystalline compound originally isolated from the root and rhizome of Polygonum cuspidatum. (E/Z)-Polydatin has anti-platelet aggregation, anti-oxidative action of low-density lipoprotein (LDL), cardioprotective activity, anti-inflammatory and immune-regulating functions .
|
-
- HY-146084
-
|
|
PCSK9
|
Metabolic Disease
|
|
PCSK9 modulator-3 (Compound 13) is a potent modulator of PCSK9 with an EC50 value of 2.46 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-3 has the potential for the research of hyperlipidemia .
|
-
- HY-146085
-
|
|
PCSK9
|
Metabolic Disease
|
|
PCSK9 modulator-4 (Compound 21) is a potent modulator of PCSK9 with an EC50 value of 0.15 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-4 has the potential for the research of hyperlipidemia .
|
-
- HY-W041171S
-
|
|
Endogenous Metabolite
|
Others
|
|
3-Chloro-L-tyrosine- 13C6 is the 13C labeled 3-Chloro-L-tyrosine[1]. 3-Chloro-L-tyrosine is a specific marker of myeloperoxidase-catalyzed oxidation, and is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima[2].
|
-
- HY-152857
-
|
LY3473329
|
Others
|
Cardiovascular Disease
|
|
Muvalaplin (LY3473329) is an orally active, selective small molecule inhibitor of lipoprotein (a) (Lp (a)) that disrupts the initial non-covalent interaction between apo(a) and apoB100, preventing the disulphide bond and Lp(a)
formation. Muvalaplin reduces the levels of Lp (a) in transgenic mice and in cynomolgus monkeys .
|
-
- HY-119265
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
LDL-IN-4 (Compound 2) inhibits human acyl-CoA:cholesterol acyltransferase-1 and -2 activities. LDL-IN-4 inhibits copper-mediated low density lipoprotein (LDL) oxidation, with an IC50 of 3 μM. LDL-IN-4 has anti-atherosclerotic biological activity .
|
-
- HY-10473
-
|
KB2115
|
Thyroid Hormone Receptor
|
Metabolic Disease
Endocrinology
|
|
Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research .
|
-
- HY-130245
-
|
|
PCSK9
|
Metabolic Disease
|
|
PCSK9 degrader 1 (Compound 16) is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to PCSK9 with a Ki of 107 nM. PCSK9 degrader 1 can involve in a protein-protein interaction with the low-density lipoprotein (LDL) receptor .
|
-
- HY-B1189
-
|
Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid
|
HMG-CoA Reductase (HMGCR)
Autophagy
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
|
|
Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .
|
-
- HY-N1881
-
|
|
Lipoxygenase
Glucosidase
|
Others
|
|
4',5-Dihydroxyflavone is a soybean LOX-1 and yeast α-Glucosidase inhibitor, with an Ki of 102.6 μM for soybean LOX-1 and an IC50 of 66 μM for yeast α-glucosidase. LOX-1 isshort for Lectin-like oxidized low-density lipoprotein receptor-1.
|
-
- HY-N10638
-
|
|
Reactive Oxygen Species
NF-κB
|
Inflammation/Immunology
|
|
N-Acetyldopamine dimer-2 (compound 2) is a N-acetyldopamine dimer that can be isolated from the yellow powder form Periostracum Cicadae with antioxidant and anti-inflammatory activities. N-Acetyldopamine dimer-2 inhibits oxidized low-density lipoprotein (LDL) oxidation, ROS generation, NO production, and NF-κB activity .
|
-
- HY-119741
-
|
|
Lipase
|
Metabolic Disease
|
|
Salacinol can be isolated from the roots of the plant Salacia reticulata. Salacinol inhibits fat metabolizing enzymes, such as pancreatic lipase (PL, IC50=12.6 mg/L), lipoprotein lipase (LPL, IC50=13.6 mg/L), and glycerophosphate dehydrogenase (GPDH), enhances the lipolysis, and exhibits antiobesity efficacy in rats .
|
-
- HY-113046
-
|
5-Methyl THF; 5-MTHF
|
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
|
|
5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases .
|
-
- HY-B0144AS1
-
|
NK-104-d5 sodium
|
Apoptosis
HMG-CoA Reductase (HMGCR)
Mitophagy
Autophagy
|
Metabolic Disease
Cancer
|
|
Pitavastatin-d5 (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
|
-
- HY-P99822
-
|
SHR-1209
|
PCSK9
|
Metabolic Disease
|
|
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Recaticimab can bind to PCSK9 and mediate its degradation, increasing the level of low-density lipoprotein (LDL) receptors on the surface of liver cells, reducing the level of LDL in plasma, thereby lowering blood lipids. Recaticimab can be used for the study of hypercholesterolemia .
|
-
- HY-P2233
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Globomycin is a lipopeptide antibiotic and a signal peptidase II (LspA) inhibitor. Globomycin inhibits processing of the prolipoprotein by binding irreversibly to the peptidase. Globomycin has toxic for the mollicute Spiroplasma melliferum with a MIC in the range 6.25-12.5 μM .
|
-
- HY-16403
-
|
|
Others
|
Cardiovascular Disease
|
|
Polythiazide is a potent and orally active thiazide diuretic agent that has antihypertensive effect. Polythiazide can decrease edema and decrease blood pressure. Polythiazide also has phototoxicity .
|
-
- HY-116175
-
|
|
Others
|
Metabolic Disease
|
|
BIBB 515 is a potent, selective and orally active 2,3-oxidosqualene cyclase (OSC) inhibitor with ED50 values of 0.2-0.5 mg/kg and 0.36-33.3 mg/kg in rats and mice (1-5 hours), respectively. BIBB 515 exerts lipid-lowering effect mainly by inhibiting the production of low-density lipoprotein (LDL) .
|
-
- HY-121212
-
|
|
Others
|
Metabolic Disease
Inflammation/Immunology
|
|
Icosabutate, an orally active ω-3 polyunsaturated fatty acid, is an aeicosapentaenoic acid (EPA) derivative. Icosabutate overcomes the drawbacks of unmodified EPA for liver targeting and improves insulin sensitivity, hepatic inflammation and fibrosis . Icosabutate is well tolerated, and efficacious in lowering non-high-density lipoprotein cholesterol (non-HDL-C) levels in persistent hypertriglyceridemia .
|
-
- HY-156081
-
|
|
Keap1-Nrf2
Apoptosis
|
Metabolic Disease
|
|
Nrf2 activator-9 (compound D-36) is an Nrf2 activator that inhibits oxidized low-density lipoprotein (oxLDL) and high glucose (HG)-induced apoptosis in HUVEC cells. Nrf2 activator-9 inhibits oxLDL and HG-induced vascular endothelial cell (VEC) injury and can effectively prevent and treat atherosclerosis .
|
-
- HY-164813
-
|
7-Ketocholesteryl-9-carboxynonanoate
|
NF-κB
|
Metabolic Disease
|
|
oxLig-1 (7-Ketocholesteryl-9-carboxynonanoate) is the lipid moiety of oxidized low-density lipoprotein (oxLDL) and is a key ligand for β-glycoprotein I (β(2)-GPI). oxLig-1 causes nuclear translocation by activating the NF-κB pathway. oxLig-1 can be used in the study of atherosclerosis (AS) .
|
-
- HY-118518
-
|
|
Calcium Channel
|
Cardiovascular Disease
Cancer
|
|
Ronipamil is a calcium ion antagonist. Ronipamil increases the specific binding and internalization of human 125I-LDL in human skin fibroblasts (HSF) and the human hepatoma cell line Hep G2 .
|
-
- HY-117219
-
|
|
Others
|
Metabolic Disease
|
|
SKF 104976 is a 3,2-carboxylic acid derivative with potent 14-alpha-demethylase (14 alpha DM) inhibitory activity. SKF 104976 inhibited 14 alpha DM activity by 50% at 2 nM in Hep G2 cell extracts. SKF 104976 inhibited the incorporation of [14C]acetate into cholesterol in intact cells at similar concentrations, accompanied by accumulation of lanosterol, and resulted in a 40-70% decrease in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) activity. SKF 104976 did not affect the uptake and degradation of low-density lipoprotein in Hep G2 cells, indicating that HMGR and low-density lipoprotein receptor activities are not coordinately regulated under these conditions. The inhibitory effect of SKF 104976 on HMGR activity remained unchanged even when the flux of carbon units in the sterol synthesis pathway was reduced by 80%. SKF 104976 did not inhibit HMGR activity under conditions where sterol synthesis was almost completely blocked by lovastatin .
|
-
- HY-10626
-
|
|
LXR
FXR
ROR
Apoptosis
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα . T0901317 activates FXR with an EC50 of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .
|
-
- HY-122816
-
|
|
Wnt
β-catenin
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
HLY78, a Lycorine (HY-N0288) derivative, is a potent activator of the Wnt/β-catenin signaling pathway. HLY78 targets the DIX domain of Axin and promotes the Axin-LRP6 (lipoprotein receptor-related protein 6) association, thus promoting LRP6 phosphorylation and Wnt signal transduction. HLY78 can be used for subarachnoid hemorrhage (SAH) research .
|
-
- HY-129982
-
|
|
Apical Sodium-Dependent Bile Acid Transporter
|
Metabolic Disease
|
|
SC-435 is an orally effective apical sodium codependent bile acid transporter (ASBT) inhibitor. SC-435 effectively removes neurotoxic bile acids and ammonia from the blood by inhibiting intestinal ASBT, thereby alleviating liver and brain damage caused by liver failure. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations .
|
-
- HY-P9928A
-
|
REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)
|
PCSK9
|
Cardiovascular Disease
|
|
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .
|
-
- HY-134154
-
|
PAzePC; Azelaoyl PC; 1-Palmitoyl-2-Azelaoyl PC
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic. Many of these substances were isolated and purified from oxLDL and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position. PAz-PC (Azelaoyl PC) is one of the predominant oxLDL species and may be one of the important structural determinants of oxLDL.
|
-
- HY-112490
-
|
|
HMG-CoA Reductase (HMGCR)
|
Cardiovascular Disease
Others
|
|
Atorvastatin calcium salt trihydrate is a drug belonging to the statin class of drugs used to lower blood cholesterol levels. Atorvastatin calcium salt trihydrate has unique chemical properties that make it an effective tool in controlling high levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the body, reducing the risk of heart attack and stroke. Atorvastatin calcium salt trihydrate works by inhibiting HMG-CoA reductase, the enzyme responsible for producing cholesterol in the liver.
|
-
- HY-B0144A
-
|
NK-104
|
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
|
Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
|
-
- HY-B0144B
-
|
NK-104 sodium
|
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
|
Pitavastatin (NK-104) sodium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin sodium inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin sodium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin sodium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
|
-
- HY-P2733C
-
|
GPO, microorganism
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Glycerol-3-phosphate oxidase, microorganism is an enzyme that catalyzes the oxidation of glycerol-3-phosphate to dihydroxyacetone phosphate, producing hydrogen peroxide in the process. Glycerol-3-phosphate oxidase is located in the mitochondria of microorganisms and is involved in the glycerol-3-phosphate cycle, regulating cellular energy metabolism. Glycerol-3-phosphate oxidase, microorganism can be used in conjunction with Lipoprotein Lipase and Glycerol Kinase to determine triglyceride levels .
|
-
- HY-130245A
-
|
|
PCSK9
|
Metabolic Disease
|
|
(R,R)-PCSK9 degrader 1 is the isomer of PCSK9 degrader 1 (HY-130245). PCSK9 degrader 1 (Compound 16) is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to PCSK9 with a Ki of 107 nM. PCSK9 degrader 1 can involve in a protein-protein interaction with the low-density lipoprotein (LDL) receptor .
|
-
- HY-108471
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
CU-CPT22 is a potent protein complex of toll-like receptor 1 and 2 (TLR1/2) inhibitor, and competes with the synthetic triacylated lipoprotein (Pam3CSK4) binding to TLR1/2 with a Ki of 0.41 µM. CU-CPT22 blocks Pam3CSK4-induced TLR1/2 activation with an IC50 of 0.58 µM .
|
-
- HY-D1005
-
|
PEG-PPG-PEG, 12600 (Average Mn)
|
LPL Receptor
|
Inflammation/Immunology
|
|
Poloxamer 407 (F127) is a nonionic surfactant that is 100% active and relatively non-toxic to cells at low concentrations, and frequently used with dye AM esters such as Indo-1 AM, Fura-2 AM, Calcein AM, Fluo-3 AM, Fluo-4 AM, Quest Fluo-8? AM and Quest Rhod-4? AM, etc. to improve their water solubility. Poloxamer 407 is also a lipoprotein lipase inhibitor .
|
-
- HY-144120
-
|
|
SARS-CoV
|
Infection
|
|
αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist . RBD: receptor-binding domain
|
-
- HY-B0144S
-
|
NK-104-d4 hemicalcium; Pitavastatin-d4 hemicalcium
|
Isotope-Labeled Compounds
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Metabolic Disease
Cancer
|
|
Pitavastatin-d4 (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].
|
-
- HY-146398
-
|
|
AMPK
|
Metabolic Disease
|
|
AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .
|
-
- HY-141572
-
|
sn-1,2-Dioleoylglycerol
|
Biochemical Assay Reagents
|
Others
|
|
ALN29882 is a glycerolipid located on the plasma membrane. It consists of two fatty acid chains covalently linked to a single glycerol molecule by means of an ester bond. 18:1 DG has been used as a source of diacylglycerol in the diacylglycerol O-acyltransferase 1 (DGAT1) assay. It is also used as a substrate in the DGAT-1 enzyme assay to evaluate compounds as potential inhibitors of DGAT-1. Suitable for lipoprotein overlay screening assays with the recombinant protein His-AtROP6.
|
-
- HY-164173
-
|
|
Toll-like Receptor (TLR)
MyD88
|
Inflammation/Immunology
|
|
LPS-PG is a lipopolysaccharide from Porphyromonas gingivalis (P. gingivalis). LPS-PG is an important virulence factor in the pathogenesis of periodontal disease and activates immune cells via Toll-like receptor 2 (TLR2), rather than the receptor for Escherichia coli (E. coli), Toll-like receptor 4 (TLR4). A lipoprotein from LPS-PG has been shown to be the major component responsible for TLR2-mediated cell activation .
|
-
- HY-117459
-
|
|
Others
|
Metabolic Disease
|
|
E-3030 free acid is a potent dual activator of peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma, exhibiting significant antidiabetic and lipid-modulating effects. E-3030 decreases blood glucose, triglyceride, non-esterified fatty acids, and insulin levels, while increasing blood adiponectin levels. E-3030 improves glucose tolerance and shows remarkable triglyceride- and non-high-density lipoprotein cholesterol-lowering effects in animal models.
|
-
- HY-B0144
-
|
NK-104 hemicalcium; Pitavastatin hemicalcium
|
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
|
Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
|
-
- HY-N2118
-
|
|
PPAR
PKA
Akt
p38 MAPK
ERK
|
Metabolic Disease
|
|
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .
|
-
- HY-P5169
-
|
|
Amino Acid Derivatives
|
Inflammation/Immunology
|
|
LVGRQLEEFL (mouse) can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death .
|
-
- HY-17504R
-
|
Rosuvastatin hemicalcium (Standard); ZD 4522 Calcium (Standard)
|
HMG-CoA Reductase (HMGCR)
Autophagy
Potassium Channel
Bacterial
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Rosuvastatin (Calcium) (Standard) is the analytical standard of Rosuvastatin (Calcium). This product is intended for research and analytical applications. Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
|
-
- HY-112490R
-
|
|
HMG-CoA Reductase (HMGCR)
|
Cardiovascular Disease
Others
|
|
Atorvastatin (calcium hydrate) (Standard) is the analytical standard of Atorvastatin (calcium hydrate). This product is intended for research and analytical applications. Atorvastatin calcium salt trihydrate is a drug belonging to the statin class of drugs used to lower blood cholesterol levels. Atorvastatin calcium salt trihydrate has unique chemical properties that make it an effective tool in controlling high levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the body, reducing the risk of heart attack and stroke. Atorvastatin calcium salt trihydrate works by inhibiting HMG-CoA reductase, the enzyme responsible for producing cholesterol in the liver.
|
-
- HY-17504D
-
|
|
HMG-CoA Reductase (HMGCR)
Potassium Channel
Autophagy
|
Cardiovascular Disease
Metabolic Disease
|
|
(3S,5R)-Rosuvastatin is the (3S,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM . Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
|
-
- HY-17504C
-
|
|
HMG-CoA Reductase (HMGCR)
Potassium Channel
Autophagy
|
Cardiovascular Disease
Metabolic Disease
|
|
(3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM . Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
|
-
- HY-P5169A
-
|
|
Amino Acid Derivatives
|
Inflammation/Immunology
|
|
LVGRQLEEFL (mouse) TFA can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) TFA exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) TFA can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death .
|
-
- HY-N0686
-
-
- HY-100976
-
-
- HY-143243
-
|
|
Apoptosis
NF-κB
Keap1-Nrf2
Reactive Oxygen Species
|
Cardiovascular Disease
|
|
Antioxidant agent-5 (compound D-6) is a potent antioxidant agent. Antioxidant agent-5 can inhibit oxLDL (oxidized low-density lipoprotein)-induced apoptosis and the expression of ICAM-1 and VCAM-1 in VECs. Antioxidant agent-5 suppresses oxLDL-induced increase of ROS level and nuclear translocation of NF-κB. Antioxidant agent-5 protects against oxLDL-induced endothelial injury by activating Nrf2/HO-1 anti-oxidation pathway .
|
-
- HY-163436
-
|
|
FXR
Cytochrome P450
RAR/RXR
PPAR
ROR
|
Metabolic Disease
|
|
F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders .
|
-
- HY-N2118R
-
|
|
PPAR
PKA
Akt
p38 MAPK
ERK
|
Metabolic Disease
|
|
Bilobetin (Standard) is the analytical standard of Bilobetin. This product is intended for research and analytical applications. Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .
|
-
- HY-117912
-
|
|
Others
|
Cardiovascular Disease
|
|
TRC210258 is a TGR5 agonist with activity to improve diabetes-associated hyperglycemia and dyslipidemia. TRC210258 promotes energy expenditure by enhancing the release of glucagon-like peptide-1. TRC210258 is able to improve glucose metabolic control in high-fat diet-induced obese mice. TRC210258 also showed improvement in lipid parameters in high-fat-fed hamsters, including reductions in plasma triglyceride and low-density lipoprotein cholesterol levels. TRC210258 improved emerging lipid-related cardiovascular risk parameters including remnant cholesterol and triglyceride clearance .
|
-
- HY-B0144R
-
|
|
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
|
Pitavastatin (Calcium) (Standard) is the analytical standard of Pitavastatin (Calcium). This product is intended for research and analytical applications. Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
|
-
- HY-159595
-
|
|
LDLR
PCSK9
|
Metabolic Disease
Inflammation/Immunology
|
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .
|
-
- HY-165061
-
|
Sciadonic acid
|
Others
|
Inflammation/Immunology
|
|
5(Z),11(Z),14(Z)-Eicosatrienoic acid (Sciadonic acid), a polyunsaturated fatty acid sourced from maritime pine seed oil, gymnospermae leaves and seeds, and freshwater gastropods, has been shown to reduce high-density lipoprotein and ApoA1 levels in transgenic mice expressing human ApoA1 when included in their diet. In vitro studies indicate that it diminishes cholesterol efflux, and when applied topically in its methyl ester form, it alleviates inflammatory processes, likely by displacing arachidonic acid from phospholipid pools and lowering concentrations of downstream inflammatory mediators such as prostaglandin E2 and leukotrienes.
|
-
- HY-126726
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.
|
-
- HY-17504AS
-
-
- HY-101448
-
|
WAY-171318
|
MMP
Apoptosis
Interleukin Related
TNF Receptor
Caspase
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
TMI-1 (WAY-171318) inhibits TNF converting enzyme (TACE) (IC50 of 8.4 nM), ADAM-TS-4, ADAM-17 and various MMPs with oral activity. TMI-1 significantly suppresses the secretion of TNF-α , alleviating collagen-induced arthritis in mice. TMI-1 inhibits cancer cell proliferation, induces apoptosis through a caspase-dependent pathway. TMI-1 also reverses TRPV1 upregulation and lowers the levels of inflammatory factors (TNF-α、IL-1β、IL-6) in nerve cells, protecting against paclitaxel-induced neurotoxicity. TMI-1 leads to changes in pro-atherogenic lipoprotein profiles, but does not affect the progression of early lesions .
|
-
- HY-134988
-
|
|
FXR
Phosphatase
Cytochrome P450
|
Inflammation/Immunology
|
|
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D0083
-
|
DiIC18(3)
|
Fluorescent Dyes/Probes
|
|
DiI is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .
|
-
- HY-D0969
-
|
DiOC18(3); 3,3'-Dioctadecyloxacarbocyanine perchlorate
|
Fluorescent Dyes/Probes
|
|
DiO is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .
|
-
- HY-D1028
-
|
|
Fluorescent Dyes/Probes
|
|
DiD is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .
|
-
- HY-D1048
-
DiR
Maximum Cited Publications
19 Publications Verification
Cy7 DiC18
|
Fluorescent Dyes/Probes
|
|
DiR is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .
|
-
- HY-D0932
-
|
Solvent Red 24; C.I. 26105
|
Dyes
|
|
Sudan IV (Solvent Red 24) is a lysochrome (fat-soluble dye) diazo dye used for the staining of lipids, triglycerides and lipoproteins on frozen sections .
|
-
- HY-D1076
-
|
|
Fluorescent Dyes/Probes
|
|
DiIC16(3) is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .
|
-
- HY-W020798
-
|
|
Fluorescent Dyes/Probes
|
|
1-Palmitoyl-2-[3-(diphenylhexatriene)propanoyl]-sn-phosphatidylcholine is a fluorescent probe with a polar phosphatidylethanolamine head group for the determination of surface lipid oxidation in lipoproteins and plasma .
|
-
- HY-D0932R
-
|
|
Dyes
|
|
Sudan IV (Standard) is the analytical standard of Sudan IV. This product is intended for research and analytical applications. Sudan IV (Solvent Red 24) is a lysochrome (fat-soluble dye) diazo dye used for the staining of lipids, triglycerides and lipoproteins on frozen sections .
|
| Cat. No. |
Product Name |
Type |
-
- HY-NP013
-
|
Mouse ox-LDL
|
Native Proteins
|
|
Oxidized low density lipoprotein (mouse) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration .
|
-
- HY-NP135
-
|
Human ox-LDL
|
Native Proteins
|
|
Oxidized low density lipoprotein (Human) (Human ox-LDL) is involved in atherogenesis. Oxidized low density lipoprotein (Human) induces endothelial dysfunction via cytoplasmic adapter protein TRAF3IP2. Oxidized low density lipoprotein (Human) can stimulate the activation of endothelial cells and the production of adhesion molecules, and inhibits eNOS activity and NO production. Oxidized low density lipoprotein (Human) can activate NLRP3 inflammasome in macrophages .
|
-
- HY-W134326
-
|
|
Biochemical Assay Reagents
|
|
Polydextrose has the effect of lowering cholesterol and plasma lipids, and can effectively reduce low-density lipoprotein cholesterol. Polydextrose significantly reduced plasma and liver cholesterol in gerbils fed with enlarged endogenous cholesterol reservoirs .
|
-
- HY-139414
-
|
|
Cell Assay Reagents
|
|
Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis .
|
-
- HY-D1005
-
|
PEG-PPG-PEG, 12600 (Average Mn)
|
Co-solvents
|
|
Poloxamer 407 (F127) is a nonionic surfactant that is 100% active and relatively non-toxic to cells at low concentrations, and frequently used with dye AM esters such as Indo-1 AM, Fura-2 AM, Calcein AM, Fluo-3 AM, Fluo-4 AM, Quest Fluo-8? AM and Quest Rhod-4? AM, etc. to improve their water solubility. Poloxamer 407 is also a lipoprotein lipase inhibitor .
|
-
- HY-141572
-
|
sn-1,2-Dioleoylglycerol
|
Drug Delivery
|
|
ALN29882 is a glycerolipid located on the plasma membrane. It consists of two fatty acid chains covalently linked to a single glycerol molecule by means of an ester bond. 18:1 DG has been used as a source of diacylglycerol in the diacylglycerol O-acyltransferase 1 (DGAT1) assay. It is also used as a substrate in the DGAT-1 enzyme assay to evaluate compounds as potential inhibitors of DGAT-1. Suitable for lipoprotein overlay screening assays with the recombinant protein His-AtROP6.
|
-
- HY-126726
-
|
|
Drug Delivery
|
|
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.
|
-
- HY-NP012
-
|
Human LDL
|
Native Proteins
|
|
Low density lipoprotein (human) is one of the five major groups of lipoprotein that carries cholesterol to various tissues such as the adrenal gland, gonads, muscle, and adipose tissue .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P6306
-
|
|
Peptides
|
Neurological Disease
|
|
CS-6253 is an agonist for ATP-binding cassette 1 (ABCA 1). CS-6253 improves the amyloid-β42/40 ratio, and affects lipoprotein metabolism in plasma. CS-6253 generates cholesterol-rich high-density lipoprotein (HDL) particles, and induces the release of microparticles .
|
-
- HY-P4073
-
|
GRN1005; Paclitaxel trevatide
|
Peptides
|
Cancer
|
|
ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system .
|
-
- HY-P10258
-
|
|
Peptides
|
Cardiovascular Disease
Inflammation/Immunology
|
|
KRES peptide is an apolipoprotein with 4 amino acid residues. KRES peptide interacts with lipids, reduces lipoprotein lipid hydroperoxides (LOOH), activates antioxidant enzymes associated with high-density lipoprotein. KRES peptide exhibits anti-inflammatory and anti-atherogenic properties. KRES peptide is orally active .
|
-
- HY-P10188
-
|
|
Peptides
|
Cardiovascular Disease
|
|
apoB (4372-4392) is a potent lipoprotein(a) assembly inhibitor, with an IC50 of 40 μM. apoB (4372-4392) can noncovalently bind to apolipoprotein(a) with high affinity .
|
-
- HY-P6306A
-
|
|
Peptides
|
Neurological Disease
|
|
CS-6253 TFA is the TFA salt form of CS-6253 (HY-P6306). CS-6253 TFA is an agonist for ATP-binding cassette 1 (ABCA 1). CS-6253 TFA improves the amyloid-β42/40 ratio, and affects lipoprotein metabolism in plasma. CS-6253 TFA generates cholesterol-rich high-density lipoprotein (HDL) particles, and induces the release of microparticles .
|
-
- HY-P10389
-
|
|
Bacterial
|
Infection
|
|
Globomycin derivative G2A (Compound G2A) is an inhibitor for lipoprotein signal peptidase II (LspA), with an IC50 of 604 nM. Globomycin derivative G2A inhibits E. coli, P. aeruginosa and A. baumannii, with MIC ranging from 12.5 to 32 μg/mL .
|
-
- HY-P10502
-
|
|
Peptides
|
Others
|
|
L57 exhibits high affinity to the low-density lipoprotein receptor-related protein 1 (LRP1) with Ki of 45 nM. L57 exhibits blood-brain barrier (BBB) permeability and plasma stability. L57 can be utilized as the carrier for CNS drug delivery .
|
-
- HY-148663
-
|
Tripalmitoyl pentapeptide
|
Peptides
|
Inflammation/Immunology
|
|
Mitogenic Pentapeptide (Tripalmitoyl pentapeptide) is an effective activator of B lymphocyte mitogen and polyclonal. Mitogen Pentapeptide is a synthetic N-terminal analog of E. coli outer membrane lipoproteins (cysteinyl-seryl-seryl-asparaginyl-alanine). Mitogenic Pentapeptide can be used for the study of immune adjuvants .
|
-
- HY-P2233
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Globomycin is a lipopeptide antibiotic and a signal peptidase II (LspA) inhibitor. Globomycin inhibits processing of the prolipoprotein by binding irreversibly to the peptidase. Globomycin has toxic for the mollicute Spiroplasma melliferum with a MIC in the range 6.25-12.5 μM .
|
-
- HY-P5169
-
|
|
Amino Acid Derivatives
|
Inflammation/Immunology
|
|
LVGRQLEEFL (mouse) can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death .
|
-
- HY-P5169A
-
|
|
Amino Acid Derivatives
|
Inflammation/Immunology
|
|
LVGRQLEEFL (mouse) TFA can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) TFA exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) TFA can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99793
-
|
MLDL1278A
|
LDLR
|
Inflammation/Immunology
|
|
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .
|
-
- HY-P99822
-
|
SHR-1209
|
PCSK9
|
Metabolic Disease
|
|
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Recaticimab can bind to PCSK9 and mediate its degradation, increasing the level of low-density lipoprotein (LDL) receptors on the surface of liver cells, reducing the level of LDL in plasma, thereby lowering blood lipids. Recaticimab can be used for the study of hypercholesterolemia .
|
-
- HY-P9928A
-
|
REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)
|
PCSK9
|
Cardiovascular Disease
|
|
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-P2752
-
|
LPL
|
Classification of Application Fields
Disease Research Fields
Cancer
|
Endogenous Metabolite
|
|
Lipoprotein lipase, Pseudomonas sp (LPL) is a multifunctional enzyme from adipose tissue, heart and skeletal muscle, islets and macrophages. Lipoprotein lipase promotes normal lipoprotein metabolism, delivery and utilization of tissue-specific substrates. Lipoprotein lipase catalyzes the rate-limiting step of lipids in blood circulation .
|
-
-
- HY-N0483
-
-
-
- HY-W041171
-
-
-
- HY-N2339
-
-
-
- HY-N5015
-
-
-
- HY-112540B
-
-
-
- HY-W510159
-
-
-
- HY-W134326
-
-
-
- HY-17504A
-
|
ZD 4522
|
Classification of Application Fields
Disease Research Fields
Cancer
|
HMG-CoA Reductase (HMGCR)
Autophagy
Potassium Channel
Bacterial
|
|
Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
|
-
-
- HY-N8353
-
|
|
Structural Classification
Natural Products
Microorganisms
Source classification
|
Others
|
|
Stachybotramide is a natural fungal metabolite with the property of modulating the activity of cholesteryl ester transfer protein (CETP). Stachybotramide stimulates the transfer of cholesteryl esters (CE) from high-density lipoprotein (HDL) to very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), increasing the transfer efficiency by 1.3- to 1.5-fold. Stachybotramide slightly reduced the transfer of cholesteryl esters from LDL and VLDL to HDL at 0.5 mM. The effect of Stachybotramide on the transfer of triglycerides (TG) from HDL was not significant. By these results, Stachybotramide was shown to preferentially stimulate the CETP-mediated transfer of cholesteryl esters from HDL to VLDL and LDL .
|
-
-
- HY-N5015R
-
-
-
- HY-N7072
-
-
-
- HY-N0120
-
-
-
- HY-B1189
-
-
-
- HY-N1881
-
-
-
- HY-119741
-
-
-
- HY-113046
-
-
-
- HY-112490
-
|
|
Cardiovascular Disease
Classification of Application Fields
Disease Research Fields
|
HMG-CoA Reductase (HMGCR)
|
|
Atorvastatin calcium salt trihydrate is a drug belonging to the statin class of drugs used to lower blood cholesterol levels. Atorvastatin calcium salt trihydrate has unique chemical properties that make it an effective tool in controlling high levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the body, reducing the risk of heart attack and stroke. Atorvastatin calcium salt trihydrate works by inhibiting HMG-CoA reductase, the enzyme responsible for producing cholesterol in the liver.
|
-
-
- HY-N2118
-
-
-
- HY-N0686
-
-
-
- HY-N2118R
-
|
|
Structural Classification
Flavonoids
Ginkgoaceae
Source classification
Phenols
Polyphenols
Plants
Biflavones
Ginkgo biloba
|
PPAR
PKA
Akt
p38 MAPK
ERK
|
|
Bilobetin (Standard) is the analytical standard of Bilobetin. This product is intended for research and analytical applications. Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B1189S
-
|
|
|
Meglutol-d3 is the deuterium labeled Meglutol[1]. Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.
|
-
-
- HY-B0144AS1
-
|
|
|
Pitavastatin-d5 (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
|
-
-
- HY-109523S
-
|
|
|
Cerivastatin-d3 sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
|
-
-
- HY-17504BS2
-
|
|
|
Rosuvastatin- 13C,d3 sodium is 13C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
|
-
-
- HY-D0932S
-
|
|
|
Sudan IV-d6 is the deuterium labeled Sudan IV(HY-D0932).Sudan IV is a lysochrome (fat-soluble dye) diazo dye used for the staining of lipids, triglycerides and lipoproteins on frozen paraffin sections .
|
-
-
- HY-W041171S
-
|
|
|
3-Chloro-L-tyrosine- 13C6 is the 13C labeled 3-Chloro-L-tyrosine[1]. 3-Chloro-L-tyrosine is a specific marker of myeloperoxidase-catalyzed oxidation, and is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima[2].
|
-
-
- HY-B0144S
-
|
|
|
Pitavastatin-d4 (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].
|
-
-
- HY-17504AS
-
|
|
|
Rosuvastatin-d3 is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM[1]. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals[2].
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-151123A
-
|
AKCEA-APO(a)-LRx sodium; ISIS 681257 sodium; TQJ230 sodium
|
|
Antisense Oligonucleotides
|
|
Pelacarsen sodium is a liver-specific antisense oligonucleotide against apolipoprotein(a) that reduces lipoprotein(a) up to 80% with good tolerability .
|
-
- HY-153497A
-
|
IONIS ANGPT-L3Rx sodium; ISIS 703802 sodium
|
|
Antisense Oligonucleotides
|
|
Vupanorsen (sodium) is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen (sodium) lowers triglycerides and atherogenic lipoproteins.
|
-
- HY-W134326
-
|
|
|
Fillers
|
|
Polydextrose has the effect of lowering cholesterol and plasma lipids, and can effectively reduce low-density lipoprotein cholesterol. Polydextrose significantly reduced plasma and liver cholesterol in gerbils fed with enlarged endogenous cholesterol reservoirs .
|
-
- HY-D1005
-
|
PEG-PPG-PEG, 12600 (Average Mn)
|
|
Emulsifiers
Solubilizing Agents
|
|
Poloxamer 407 (F127) is a nonionic surfactant that is 100% active and relatively non-toxic to cells at low concentrations, and frequently used with dye AM esters such as Indo-1 AM, Fura-2 AM, Calcein AM, Fluo-3 AM, Fluo-4 AM, Quest Fluo-8? AM and Quest Rhod-4? AM, etc. to improve their water solubility. Poloxamer 407 is also a lipoprotein lipase inhibitor .
|
-
- HY-151123
-
|
AKCEA-APO(a)-LRx; ISIS 681257; TQJ230
|
|
Antisense Oligonucleotides
|
|
Pelacarsen (AKCEA-APO(a)-LRx) is a liver-specific antisense oligonucleotide against apolipoprotein(a) that reduces lipoprotein(a) up to 80% with good tolerability .
|
-
- HY-153492A
-
|
AMG 890 sodium; ARC-LPA sodium
|
|
siRNAs
|
|
Olpasiran sodium is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver.
|
-
- HY-153497
-
|
IONIS ANGPT-L3Rx; ISIS 703802
|
|
Antisense Oligonucleotides
|
|
Vupanorsen is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen lowers triglycerides and atherogenic lipoproteins.
|
-
- HY-W719862
-
|
|
|
Cationic Lipids
|
|
16:0 PDP PE belongs to a class of head group modified functionalized lipids. 16:0 PDP PE has been used in preparation of rhodamine high-density lipoprotein nanoparticle (Rh-HDL NP) synthesis.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![1-Palmitoyl-2-[3-(diphenylhexatriene)propanoyl]-sn-phosphatidylcholine](http://file.medchemexpress.eu/product_pic/hy-w020798.gif)
